| 【Sector Research】China Heavy Duty Truck – Lower industry forecast on weak recovery; D/G Weichai-A; BUY Weichai-H & Sinotruk on valuation |
| 【Company Research】Geely (175 HK) – Low earnings quality; Not an inflection point yet |
| 【Company Research】AAC Technologies (2018 HK) – Not out of the woods yet; more downside to 2022 earnings |
| 【Fixed Income Research】XIAOMI - Solid FY2021 result, tempered by its high spending appetite |
| 【Company Research】ZTE (763 HK) – Overhang removed; Focus on core business development |
| 【Company Research】Ever Sunshine (1995 HK) – Downgrade to Hold on margin and community VAS outlook |
| 【Fixed Income Research】YLLGSP - Initiating coverage with buy recommendations on YLLGSPs |
| 【Company Research】WuXi Biologics (2269 HK) – Growth momentum intact |
| 【Company Research】Tencent (700 HK) – Looking into 2H22E recovery |
| 【Company Research】InnoCare Pharma (9969 HK) – A successful commercial year for orelabrutinib |
公司地址：香港中环花园道三号冠君大厦45-46楼
电话：（852）3900-0888 传真：（852）3761-8788
招银国际版权所有 Copyright © 2019-2025 CMB International Capital Corporation Limited. All rights reserved.
